Recruiting OBSERVATIONAL NCT06831071
Evaluation of Hypoxia in Primary Melanoma
Prospective Evaluation of Hypoxia in Primary Melanoma
Sponsor: Hypoxyprobe
Conditions
Melanoma
Interventions
Pimonidazole
Updated 2 times since 2025 Last updated: May 5, 2025 Started: Apr 9, 2025 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06831071, this observational or N/A phase trial focuses on Melanoma and remains actively recruiting participants. Sponsored by Hypoxyprobe, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Jun 2025 — Present [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2025 — Jun 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Hypoxyprobe
- Yana Najjar
Data source: University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .